Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records

Paul Yamauchi; Chi-Chang Chen; Yao Ding; et al.

doi:10.25251/skin.3.2.13

Paul Yamauchi
Chi-Chang Chen
Yao Ding
et al.

Keywords

Abstract

Abstract not available.

Disclosures: Study sponsored by Novartis.

Poster PDF

Published

Mar 11, 2019

DOI https://doi.org/10.25251/skin.3.2.13

How to Cite

Yamauchi, P., Chen, C.-C., Ding, Y., & al., et. (2019). Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records. SKIN The Journal of Cutaneous Medicine, 3(2), 173. https://doi.org/10.25251/skin.3.2.13

Issue

Vol. 3 No. 2 (2019)

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Matthew Zirwas, Zoe Draelos, Janet Dubois, Leon Kircik, Angela Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence Green, Scott Guenthner, Laura Ferris, Seth Forman, Steven Kempers, Edward Lain, Charles Lynde, David Pariser, David Pariser, Darryl Toth, paul Yamauchi, Patrick Burnett, David Berk, A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Jerry Bagel, Linda Stein Gold, James Del Rosso, Neal Bhatia, Sandy Johnson , Paul Yamauchi, Angela Moore, Anna Tallman, Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Abby Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al., Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
Andrew Blauvelt, Lars Iversen, Sandy McBride, Melinda Gooderham, Petra Staubach, Paul Yamauchi, Fabienne Staelens, Veerle Vanoorden, Katy White, Paolo Gisondi, Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Richard G Langley, Jeffrey Crowley, Melinda Gooderham, Kim A Papp, Neil J Korman, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Aditya K Gupta, Paul Yamauchi, Jeffrey Parno, Alan M Mendelsohn, Stephen J Rozzo, Kimberly Eads, Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2 , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Kim A Papp, Andrew Blauvelt, John Sullivan, Et al., Efficacy of Ixekizumab in Patients Previously Treated with IL-17 Inhibitors , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
Linda Stein Gold, Paul Yamauchi, David Pariser, Zhenyi Xu, Marie L Osterdal, Jerry Bagel, Treatment with Fixed Combination Calcipotriol 50 ug/g and Betamethasone Dipropionate 0.5 mg/g Foam Provides Rapid and Significant Itch Relief in Patients with Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Alice Gottlieb, Alan Menter, Paul Yamauchi, George Han, Radhakrishnan Pillai, Tina Lin, Abby Jacobson, Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Linda Stein Gold, James Q Del Rosso, Neal D Bhatia, et al., Efficacy and Safety of FMX103 (1.5% Minocycline Foam) in the Treatment of Moderate to Severe Papulopustular Rosacea: Results from two Phase 3 Randomized, Multicenter, Double Blind, Vehicle Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)

1 2 3 > >>

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Most read articles by the same author(s)